The PARP inhibitor olaparib is currently approved for the treatment of PCa patients harboring a somatic or germline Breast Cancer 1 or 2 (BRCA1/2) mutation, similarly, deficiency of several other DNA damage repair (DDR) proteins has been detected in (late stage) PCa patients. Here, BRCA1 is linked to breast carcinoma.